An open label, multi-centre, dose escalation/expansion, phase1 study of IMU-201 (PD1-Vazz) a B-cell immunotherapy in adults with non-small cell lung cancer
- Park, John (Primary Chief Investigator)
- Chapman, Nicola (Clinical Trial Unit Staff)
Project: Research